Vicore Pharma Holding AB (publ)

Stockholm Stock Exchange VICO.ST

Vicore Pharma Holding AB (publ) Cash and Short-Term Investments for the year ending December 31, 2023

Vicore Pharma Holding AB (publ) Cash and Short-Term Investments is NA for the year ending December 31, 2023. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.
  • Vicore Pharma Holding AB (publ) Cash and Short-Term Investments for the year ending December 31, 2022 was USD 25.00 M, a -38.84% change year over year.
  • Vicore Pharma Holding AB (publ) Cash and Short-Term Investments for the year ending December 31, 2021 was USD 40.87 M, a 5.83% change year over year.
  • Vicore Pharma Holding AB (publ) Cash and Short-Term Investments for the year ending December 31, 2020 was USD 38.62 M, a 37.17% change year over year.
  • Vicore Pharma Holding AB (publ) Cash and Short-Term Investments for the year ending December 31, 2019 was USD 28.15 M, a 11.37% change year over year.
Key data
Date Cash and Short-Term Investments Receivables Inventory Goodwill
Market news
SV Wall Street
Stockholm Stock Exchange: VICO.ST

Vicore Pharma Holding AB (publ)

CEO Mr. Ahmed S. Mousa J.D.
IPO Date Dec. 10, 2015
Location Sweden
Headquarters Kronhusgatan 11
Employees 29
Sector Healthcare
Industries
Pharmaceuticals 3D Printing Biotechnology Clinical Trials Drugstores & Retail Pharmacies Eyewear Plastics Vaccines
Description

Vicore Pharma Holding AB (publ) engages in the research and development of pharmaceutical products for the treatments for rare lung diseases. The company is developing VP01, a small molecule compound for oral administration that is in phase II clinical trial for the treatment of interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and COVID-19; and VP02, a formulation and delivery route for an existing immunomodulatory compound, which is preclinical trials to treat patients with IPF. It has a cooperation and development agreement with Emeriti Bio AB; license agreement with Nanologica AB (publ); and a collaboration agreement with Alex Therapeutics AB for the development and clinical validation of a digital therapeutic (DTx) built on the Alex DTx platform. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Gothenburg, Sweden.

StockViz Staff

February 5, 2025

Any question? Send us an email